Please use this identifier to cite or link to this item: https://dora.health.qld.gov.au/qldresearchjspui/handle/1/7607
Title: Integrating International Consensus Guidelines for Anticancer Drug Dosing in Kidney Dysfunction (ADDIKD) into everyday practice
Authors: Sandhu, Geeta
Adattini, Josephine
Armstrong Gordon, Evangeline
O'Neill, Niamh
Bagnis, Corrinne
Boddy, Alan V
Chambers, Pinkie
Flynn, Alex
Hamilton, Brett
Ibrahim, Karim
Johnson, David W
Karapetis, Christos
Kelly, Aisling
Kerr, Kimberley-Ann
Kichenadasse, Ganessan
Kliman, David S
Kurkard, Craig
Liauw, Winston
Lucas, Catherine
Mallett, Andrew J
Malyszko, Jolanta
McCaughan, Georgia
Michael, Michael
Mirkov, Sanja 
Morris, Emma
Pollock, Carol A
Roberts, Darren M
Routledge, David J
Scuderi, Carla 
Shingleton, Julia
Shortt, Jake
Siderov, Jim
Sprangers, Ben
Stein, Brian N
Tey, Amanda
Webber, Kate
Wichart, Jenny
Wong, Rachel
Ward, Robyn L
Issue Date: 2025
Source: Sandhu G, Adattini J, Armstrong Gordon E, O'Neill N, Bagnis C, Boddy AV, Chambers P, Flynn A, Hamilton B, Ibrahim K, Johnson DW, Karapetis C, Kelly A, Kerr KA, Kichenadasse G, Kliman DS, Kurkard C, Liauw W, Lucas C, Mallett AJ, Malyszko J, McCaughan G, Michael M, Mirkov S, Morris E, Pollock CA, Roberts DM, Routledge DJ, Scuderi C, Shingleton J, Shortt J, Siderov J, Sprangers B, Stein BN, Tey A, Webber K, Wichart J, Wong R, Ward RL; ADDIKD Working Group. Integrating International Consensus Guidelines for Anticancer Drug Dosing in Kidney Dysfunction (ADDIKD) into everyday practice. EClinicalMedicine. 2025 Mar 25;82:103161. doi: 10.1016/j.eclinm.2025.103161. PMID: 40290844; PMCID: PMC12034076.
Journal Title: EClinicalMedicine
Journal: eClinical Medicine
Abstract: Part 2 of the International Consensus Guideline on Anticancer Drug Dosing in Kidney Dysfunction (ADDIKD) offers drug-specific consensus recommendations based on both evidence and practical experience. These recommendations build upon the kidney function assessment and classification guidelines established in Part 1 of ADDIKD. Here we illustrate how dosing recommendations differ between ADDIKD and existing guidance for four commonly used drugs: methotrexate, cisplatin, carboplatin and nivolumab. We then describe how the recommendations can be distilled into practice points for methotrexate and cisplatin. While ADDIKD is a significant improvement from previous guidelines, adoption of this new guideline requires further endorsement from key external stakeholders, 'change championing' by clinicians locally and encouraging its integration into existing reference sources, clinical trial protocols and electronic prescribing systems. Development of the ADDIKD guideline is funded by the NSW Government as part of the Cancer Institute NSW and received no funding from external commercial sources.
Description: Cairns & Hinterland Hospital and Health Service (CHHHS) affiliated author: Sanja Mirkov
DOI: 10.1016/j.eclinm.2025.103161
Keywords: Chemotherapy;Drug dosing;Kidney dysfunction;Renal;Oncology;Haematology;Pharmacokinetics
Type: Article
Appears in Sites:Cairns & Hinterland HHS Publications
Queensland Health Publications

Show full item record

Page view(s)

62
checked on Jun 24, 2025

Google ScholarTM

Check

Altmetric


Items in DORA are protected by copyright, with all rights reserved, unless otherwise indicated.